| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9312237 | Urology | 2005 | 5 Pages |
Abstract
These data contribute toward allaying concerns that the use of nonimmunosuppressant immunophilin ligand therapy for the improvement of erectile function recovery after radical prostatectomy will promote recurrent prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Arthur L. Burnett, Melissa F. Kramer, Susan Dalrymple, John T. Isaacs,